(1996). Mazumder A: The effect of hydroxychloroquine on alloreactivity and its potential use for graftversus-host disease. Bone Marrow Transplant
(1988). Mechanism of the neurotoxic and hepatotoxic effects of carbon disulfide. Drug Metabol Drug Interact
(1995). Mechanisms and genes of cellular suicide.
(2002). Merajver SD: Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia
(1995). Nuclear changes in apoptosis.
(2000). Pharmacological proteasome inhibitors and their therapeutic potential. Exp Opin Ther Patents
(1999). PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res
(1971). Prophylactic value of clioquinol against travellers' diarrhoea. Lancet
(1999). Proteasome inhibitors as potential novel anticancer agents. Drug Resist Updat
(2004). QP: Copper storage diseases: Menkes, Wilsons, and cancer. Front Biosci
(1998). QP: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ
(2004). QP: Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem Pharmacol
(2005). RW: Suppression of experimental abdominal aortic aneurysms in mice by treatment with pyrrolidine dithiocarbamate, an antioxidant inhibitor of nuclear factor-kappaB. J Vasc Surg
(1996). S: Apoptosis induction resulting from proteasome inhibition.
(2000). SB: Tumour vasculature as a target for anticancer therapy. Cancer Treat Rev
(2005). SE: Anticancer activity of the antibiotic clioquinol. Cancer Res
(2002). Serum and tissue trace elements in patients with breast cancer in Taiwan. Biol Trace Elem Res
(1984). Serum ceruloplasmin and copper levels in patients with primary brain tumors. Klin Wochenschr
(1977). Serum copper and ceruloplasmin levels in patients with neoplasias localized in the stomach, large intestine or lung. Tumori
(1994). Serum trace elements and Cu/Zn ratio in malignant lymphomas in children.
(1993). Serum ultrafiltrable copper, total copper and caeruloplasmin concentrations in gynaecological carcinomas. Ann Clin Biochem
(2000). Sondak VK, et al.: Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res
(1980). SR: The zinc and copper content of blood leucocytes and plasma from patients with benign and malignant prostates. Clin Chim Acta
(2000). Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals. Neuropathology
(2003). Tammer A, et al.: Metalprotein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol
(1999). TH: Association between oxidative stress and changes of trace elements in patients with breast cancer. Clin Biochem
(1999). The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem
(1994). The ubiquitin-proteasome proteolytic pathway. Cell
(1999). Thiele DJ: Pipes and wiring: the regulation of copper uptake and distribution in yeast. Trends Microbiol
(2001). Treatment with a copper-zinc chelator markedly and rapidly inhibits betaamyloid accumulation in Alzheimer's disease transgenic mice. Neuron
(1995). Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol
(2003). Udupa SL: Copper and ceruloplasmin status in serum of prostate and colon cancer patients.
(1997). VP: Serum levels of copper, zinc, iron and ceruplasmin in oral leukoplakia and squamous cell carcinoma.
(1995). W: Proteasome from Thermoplasma acidophilum: a threonine protease. Science
(2000). Wilding G: Angiogenesis inhibitors. New agents in cancer therapy. Drugs Aging